| Catalog No. | AB941014 |
|---|
| Applications | ELISA |
|---|
| Host species | Rabbit |
|---|
| Isotype | IgG |
|---|
| Clonality |
Polyclonal |
| Immunogen |
Ranibizumab |
| Target |
Rabbit polyclonal to Lucentis. |
| Specificity |
The product is specific for Ranibizumab. This antibody serves as an excellent positive control for Ranibizumab immunogenicity (ADA) assays. |
| Endotoxin level |
Please contact with the lab for this information. |
| Purification |
Purified by antigen affinity column. |
| Accession |
CAS: 347396-82-1 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Product Usage Information |
| Application |
Dilution |
| ELISA |
1:5000-1:20000 |
| IHC |
1:50-1:500 |
| WB |
1:500-1:2000 |
|
|---|
| Stability and Storage |
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles. |
| Background | Ranibizumab with trade name Lucentis, is an FDA-approved drug for the treatment of patients with neovascular (Wet) age-related macular degeneration (AMD) and macular edema following retinal vein occlusion (RVO). It is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment. Ranibizumab binds to vascular endothelial growth factor A (VEGF-A) and blocks its activity. Antibodysystem Anti-Ranibizumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Ranibizumab.
|
|---|
| Note |
For research use only. |
中文
English
